Regenxbio (RGNX) Tops Q4 EPS by 12c

Regenxbio (NASDAQ: RGNX) reported Q4 EPS of ($1.01), $0.12 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $21.21 million versus the consensus estimate of $23.47 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Stripe, Advent In Talks To Buy Paypal - WSJ
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results